Biotechnology investing isn't for the faint of heart. Long investment periods, the perils of the FDA approval process, and a high mortality rate are a few of the issues that confront biotechnology investors. Venture capital investing in biotechnology start-ups has fallen off over the past few years, partly due to poor returns, but also because the long investment period doesn't work well in the typical 10-12 year life span of a venture capital fund. Xconomy.com has a good article on the new trends in biotechnology investing that are emerging to address some of these issues, and it's worth a read. Here's the link: http://www.xconomy.com/national/2012/04/09/investing-in-biotech-isnt-just-for-the-investors-anymore/
About this Blog
This Blog is a collection of thoughts on a variety of topics of interest to me, including:
All original works on this site are
© 2011-2020 Allen J. Latta. All rights reserved. Neither this website nor any portion thereof may be reproduced or used in any manner whatsoever
without the express prior written permission of Allen J. Latta.
LP Corner® is a registered trademark of Campton Private Equity Advisors. Used with permission.
DISCLAIMER: Readers of this Blog are not to construe it as investment, legal, accounting or tax advice, and it is not intended to provide the basis for the evaluation of any investment. Readers should consult with their own investment, legal, accounting, tax and other advisors to the determine the benefits and risks of any investment.
Private equity investments involve significant risks, including the loss of the entire investment.
This Blog does not constitute an offer to sell or the solicitation of an offer to buy any security.